Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers

Fig. 3

ERX-11 enhances palbociclib ability to reduce tumor growth in preclinical models of endocrine therapy resistance. ad Following implantation and growth of ER+ tamoxifen-resistant xenografts (n = 4 tumors/group), mice were treated with vehicle, ERX-11 (10 mg/kg/day), palbociclib (50 mg/kg/day), or in combination. Tumor volume (a), body weight (b), and Ki-67 status of vehicle and drug-treated tumors were shown (c, d). Following implantation and growth of ER+ letrozole resistant xenografts (n = 7 tumors/group), mice were treated with vehicle or ERX-11(10 mg/kg/day), palbociclib (50 mg/kg/day), or in combination. Tumor volume (e), body weight (f), and Ki-67 status of vehicle and drug-treated tumors were shown (g, h) (*p < 0.05, ***p < 0.001, ****p < 0.0001)

Back to article page